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Due to the possibility to cure the disease, treatment duration in HCV is limited to a
maximum of 48 weeks. The lengths of use of direct acting agents (DAA=s) are
significantly different: 12 weeks with telaprevir vs. 24, 32 or 44 weeks with boce-
previr. These factors make the implementation of futility rules in economic models
critical. OBJECTIVES: To provide an insight on the proper application of the futility
rules in economic evaluations of DAA=s. METHODS: A decision tree model was
developed to assess cost-efficacy for each DAA, considering 4 patient types: naïve,
relapsers, partial responders, and null responders. Average acquisition costs have
been estimated with and without the use of futility rules; if these rules are used,
corresponding salvage treatment costs were included. The efficacy of triple therapy
treatment was defined by patient type based on each DAA’s summary of product
characteristics. Cost per patient with sustained virological response (SVR) and the
number of cured and not cured patients was calculated with a fixed budget.
RESULTS: For a 10 million EUR investment in each patient type for either DAA,
using telaprevir offers maximum cured (726 vs. 587) and minimum non-cured
patients (399 vs. 517) if futility rules are not considered. If the futility rules are used,
there are still maximum cured patients (759 vs. 734) and minimum non-cured
patients (450 vs. 697) when telaprevir is used. We performed one-way and two-way
sensitivity analyses and the overall conclusion does not change vs. boceprevir.
CONCLUSIONS: Telaprevir offers maximum cured and minimum non-cured pa-
tients regardless of the futility rule consideration when compared to boceprevir. If
stopping rules are considered in economic evaluations for the treatment of HCV, an
appropriate horizon timeline should also be considered to capture future unavoid-
able costs of non-cured patients: salvage treatment and/or potential disease pro-
gression.
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OBJECTIVES: Invasive Fungal Infections (IFIs) present a major issue in clinical prac-
tice, due to their high morbidity and mortality rates. In a pivotal multicentre, ran-
domized clinical trial posaconazole prophylaxis prevented IFIs more effectively
than did either fluconazole or itraconazole, and improved overall survival. The aim
of this study was to perform an economic evaluation of the afore-mentioned ther-
apeutic strategies for IFI prophylaxis in neutropenic patients, in the Greek health
care setting.METHODS:A decision analytic model was developed, which described
the course of neutropenic patients under posaconazole or standard azole (flucona-
zole or itraconazole) treatment. The effectiveness data for each treatment regimen
were derived from published results of a pivotal, multicentre, randomized clinical
trial. The cost and health care resources utilization data used, depict Greek clinical
practice and are derived from official Greek sources. In order to obtain some of the
model imputs, expert opinion from Greek Hematologists specializing in treating
IFIs, was also used. RESULTS: Prophylaxis with Posaconazole resulted in fewer IFIs
(0,05 vs. 0,11 per patient) compared to treatment with fluconazole or itraconazole,
during the first 100 days from initiation of prophylaxis treatment. The cost per
avoided IFI with Posaconazole was 6,455€, while the cost for every incremental life
year gained (LYG) was estimated at 24,196€. Extensive sensitivity analyses (one-
way and probabilistic) corroborated the base-case results. CONCLUSIONS: : The
utilization of Posaconazole for prophylaxis of IFIs in hematology patients with
neutropenia is a therapeutic strategy that provides superior clinical efficacy, while
being cost-effective compared to alternative therapies.
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OBJECTIVES: To estimate the disease burden and economic impact of the 10-valent
pneumococcal non-typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine
(PHiD-CV) compared with 13-valent pneumococcal conjugate vaccine (PCV13) in Finland
based on recently generated vaccine efficacy/effectiveness data. To date, vaccine efficacy
of the second generation pneumococcal conjugate vaccines (PCVs) on invasive pneumo-
coccal disease (IPD) and pneumonia has been extrapolated based on 7-valent PCV (PCV7)
efficacy data and serotype distribution. Impact of PCVs on IPD and pneumonia is now
observed inpost-marketingsettings inseveralcountriesandtheeffectivenessofPHiD-CV
against IPD has recently been demonstrated in a clinical trial in Finland. METHODS: A
Markov cohort model was used to estimate the clinical and cost burden of pneu-
mococcal and NTHi-related diseases in a birth cohort over lifetime and to measure
the clinical and economic impact of PHiD-CV compared with PCV13 in Finland.
Age-specific incidences of IPD, pneumonia and acute otitis media (AOM) and direct
medical costs were calculated and used as input data. Only the direct effect of
vaccination was assessed. Outcomes were measured by reduction in disease bur-
den, costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness
ratio. RESULTS: The model predicts that PHiD-CV and PCV13 may have a similar
impact on IPD and pneumonia in a pediatric population. PHiD-CV is estimated to
prevent an additional 26,576 AOM cases and 2,502 myringotomy procedures versus
PCV13 in a country with a birth cohort of 57,000 infants. This translates in an
additional reduction of medical costs by EUR 8,470,547 (discounted with 3%). Cost-
effectiveness analysis showed that PHiD-CV provides 135 more QALYs (discounted)
while saving cost compared with PCV13. Universal infant vaccination with
PHiD-CV provides more HE benefits than PCV13. CONCLUSIONS: Nation-wide in-
fant vaccination with PHiD-CV in Finland is projected to improve health outcomes
and be a cost-saving strategy. Funding: GlaxoSmithKline Biologicals SA.
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OBJECTIVES: Chickenpox is an infectious disease caused by the varicella-zoster virus
(VZV) which is recognized as a public health problem for its high infectivity that can lead
to serious complications and high costs both for society and health system. Published
studies indicate that in Italy about 500,000 people are affected by varicella each year. This
analysis estimates the incremental cost-effectiveness ratio (ICER) of replacing MMR vac-
cineby introducingMMRVvaccine inthecurrentschedule in Italy.Thehigherriskof fever
episodes and febrile seizures associated with MMRV compared with MMR vaccination
and the conservative assumption on exogenous immunity boosting on zoster incidence
were taken into account.METHODS: An age-structured dynamic model was used to
simulate the evolution of varicella and herpes zoster, both in current schedule and
with replacement of MMR by MMRV with a lifetime horizon. Two scenarios were
evaluated on the basis of first and second dose of vaccination coverage: 85% and
70% for the first scenario, 70% and 50% for the second scenario. It was assumed that
MMR would be completely replaced by MMRV within 5 years. RESULTS: For both
scenarios tested at the fifth year the ICER was 13,765 and 12,911 €/QALY respec-
tively for the first and second scenario. There were significant savings for outpa-
tient, hospitalisation and indirect costs. Varicella cases avoided following the com-
plete implementation of MMRV (in 5 years) were respectively 677,738 and 537,584.
CONCLUSIONS: This analysis, that considers benefits and risks of MMRV vaccines,
indicates that the implementation of MMRV would provide a benefit in terms of
cases and costs avoided and is likely to be cost-effective. From the NHS perspective
the ICER supports the introduction of MMRV. Benefits of vaccination increase in
correspondence to high vaccination coverage.
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OBJECTIVES: To analyze the cost-effectiveness of mass primovaccination of new-
borns in the Slovak Republic with BCG vaccine against tuberculosis compared to
the cost-effectiveness of selective primovaccination of specific groups, as well as to
there being no vaccination at all.METHODS: To compare cost-effectiveness, meth-
ods were chosen as to determine direct cost of illness and minimization of costs
from the perspective of health insurance companies. Additionally, the closely re-
lated parameter of direct costs needed to prevent one case of active tuberculosis in
children aged 0 to 14 years was analyzed. The own adapted model was used.
RESULTS: Data used were obtained from the Public Health Authority of the Slovak
Republic, National Tuberculosis Registry, State Institute for Drug Control, Statisti-
cal Office of the Slovak Republic, Ministry of Health, and from Health Insurance
Companies. We assumed that the vaccine will have a 15-year effect, at an average
effectiveness of 63.3% in preventing active tuberculosis. The costs for preventing
one case of active tuberculosis in children aged 0 to 14 years would be € 794.69 lower
if mass vaccination of newborns is applied than if all vaccination was to be discon-
tinued. For selective vaccination of newborns, the cost of preventing one case of
active tuberculosis in children aged 0 to 14 years would be € 440.02 lower than if all
vaccination were to be discontinued. Finally, mass vaccination of newborns results
in the cost of preventing one case of active tuberculosis in children aged 0 to 14
years being € 1 731.75 lower than for selective vaccination. CONCLUSIONS: The
most advantageous strategy for the state would be to implement mass vaccination
of newborns against tuberculosis. A shift to selective vaccination would only be
beneficial if the costs for treatment of tuberculosis were to decrease dramatically.
The least useful strategy would be to discontinue vaccination.
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OBJECTIVES: Although not directly compared, both Atazanavir and Darunavir are
possible options for the treatment of naive HIV-infected patients, as the third agent
(Ritonavir-boosted protease-inhibitor), to be used together with two nucleoside-
analogue, reverse-transcriptase inhibitors. The objective of this study was to eval-
uate the incremental cost-effectiveness ratio (ICER) of Darunavir compared to
Atazanavir in naive HIV-infected patients, according to the Belgian third party
payer perspective. METHODS: A cost-effectiveness model was developed to com-
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